Is GIP a glucagon cell constituent?

The Human and Mouse Islet Peptidome: Effects of Obesity and Type 2 Diabetes, and Assessment of Intraislet Production of Glucagon-like Peptide-1

To characterize the impact of metabolic disease on the peptidome of human and mouse pancreatic islets, LC-MS was used to analyze extracts of human and mouse islets, purified mouse alpha, beta, and delta cells, supernatants from mouse islet incubations, and plasma from patients with type 2 diabetes. Islets were obtained from healthy and type 2 diabetic human donors, and mice on chow or high fat diet. All major islet hormones were detected in lysed islets as well as numerous peptides from vesicular proteins including granins and processing enzymes. Glucose-dependent insulinotropic peptide (GIP) was not detectable. High fat diet modestly increased islet content of proinsulin-derived peptides in mice. Human diabetic islets contained increased content of proglucagon-derived peptides at the expense of insulin, but no evident prohormone processing defects. Diabetic plasma, however, contained increased ratios of proinsulin and des-31,32-proinsulin to insulin. Active GLP-1 was detectable in human and mouse islets but 100-1000-fold less abundant than glucagon. LC-MS offers advantages over antibody-based approaches for identifying exact peptide sequences, and revealed a shift toward islet insulin production in high fat fed mice, and toward proglucagon production in type 2 diabetes, with no evidence of systematic defective prohormone processing.

Establishment of novel specific assay for short-form glucose-dependent insulinotropic polypeptide and evaluation of its secretion in nondiabetic subjects

The short‐form glucose‐dependent insulinotropic polypeptide (GIP) (1–30) is released from islet alpha cells and promotes insulin secretion in a paracrine manner in vitro. However, it is not well elucidated how GIP (1–30) is involved in glucose metabolism in vivo, since a specific assay system for GIP (1–30) has not yet been established. We first developed a sandwich enzyme‐linked immunosorbent assay (ELISA) specific for GIP (1–30) by combining a novel antibody specific to the GIP (1–30) C terminus with the common antibody against GIP N terminus. Then, we explored cross‐reactivities with incretins and glucagon‐related peptides in this ELISA. GIP (1–30) amide, but not GIP (1–42), GLP‐1, or glucagon increased absorbance in a dose‐dependent manner. We next measured plasma GIP (1–30) concentrations in nondiabetic participants (ND) during a 75‐g oral glucose tolerance test or cookie meal test (carbohydrates 75 g, lipids 28.5 g, proteins 8.5 g). Both glucose and cookie load increased GIP (1–30) concentrations in ND, but the increases were much lower than those of GIP (1–42). Furthermore, the DPP‐4 inhibitor significantly increased GIP (1–30) concentrations similarly to GIP (1–42) in ND. In conclusion, we for the first time developed an ELISA specific for GIP (1–30) and revealed its secretion in ND.

Update on prevalence and distribution pattern of tick-borne diseases among humans in India: a review

In the present scenario, tick-borne diseases (TBDs) are well known for their negative impacts on humans as well as animal health in India. The reason lies in their increased incidences due to global warming, environmental and ecological changes, and availability of suitable habitats. On a global basis, they are now considered a serious threat to human as well as livestock health. The major tick-borne diseases in India include Kyasanur forest disease (KFD), Crimean-congo hemorrhagic fever (CCHF), Lyme disease (LD), Q fever (also known as coxiellosis), and Rickettsial infections. In recent years, other tick-borne diseases such as Babesiosis, Ganjam virus (GANV), and Bhanja virus (BHAV) infections have also been reported in India. The purpose of this paper is to review the history and the current state of knowledge of tick-borne diseases in the country. The conclusion of this review is extending the requirement of greater efforts in research and government management for the diagnosis and treatment and as well as prevention of these diseases so that tick-borne disease burden should be minimizing in India.

Alternative form of glucose-dependent insulinotropic polypepide and its physiology

Glucose‐dependent insulinotropic polypepide (GIP) was first extracted from porcine gut mucosa and identified as “incretin” decades ago. Though early studies have shown the possible GIP isoforms by gel filtration profiles from porcine or human intestinal extracts analyzed by radioimmunoassay (RIA), GIP is currently believed to consist of 42 amino acids (GIP1‐42), which are released from gut K‐cells and promote postprandial insulin release. In fact, GIP1‐42 is usually processed from proGIP by the action of prohormone convertase (PC) 1/3 in the gut. GIP expression is occasionally found in the intestinal glucagon‐like peptide‐1‐secreting cells, suggesting gene expression of both GIP and proglucagon can co‐exist in identical cells. However, GIP1‐42 immunoreactivity is rarely found in α‐cells or other pancreatic endocrine cells of wild‐type mammals. Interestingly, we found that short‐form GIP1‐30 is expressed in and released from pancreatic α‐cells and a subset of enteroendocrine cells through proGIP processing by PC2. GIP1‐30 is also insulinotropic and modulates glucose‐stimulated insulin secretion in a paracrine manner. It is also suggested that short‐form GIP1‐30 possibly plays a crucial role for the islet development. It has not been well elucidated whether expression of GIP1‐30 is modulated in the diabetic status, and whether GIP1‐30 might have therapeutic potentials. Our preliminary data suggest that short‐form GIP1‐30 might play important roles in glucose metabolism.

Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion

BACKGROUND & AIMS

Glucose-dependent insulinotropic polypeptide (GIP) and the proglucagon product glucagon-like peptide-1 (GLP-1) are gastrointestinal hormones that are released in response to nutrient intake and promote insulin secretion. Interestingly, a subset of enteroendocrine cells express both GIP and GLP-1. We sought to determine whether GIP also might be co-expressed with proglucagon in pancreatic alpha-cells.

METHODS

We assessed GIP expression via reverse-transcription polymerase chain reaction, in situ hybridization, and immunohistochemistry. We developed a novel bioassay to measure GIP release from isolated islets, compared the biological activities of full-length and truncated GIP, and assessed the impact of immunoneutralization of islet GIP on glucose-stimulated insulin secretion in isolated islets.

RESULTS

GIP messenger RNA was present in mouse islets; GIP protein localized to islet alpha-cells of mouse, human, and snake pancreas, based on immunohistochemical analyses. However, using a C-terminal GIP antibody, immunoreactivity was detected in islets from prohormone convertase (PC) 2 knockout but not wild-type mice. Bioactive GIP was secreted from mouse and human islets after arginine stimulation. In the perfused mouse pancreas, GIP(1-42) and amidated GIP(1-30) had equipotent insulinotropic actions. Finally, immunoneutralization of GIP secreted by isolated islets decreased glucose-stimulated insulin secretion.

CONCLUSIONS

GIP is expressed in and secreted from pancreatic islets; in alpha-cells, PC2 processes proGIP to yield a truncated but bioactive form of GIP that differs from the PC1/3-derived form from K-cells. Islet-derived GIP promotes islet glucose competence and also could support islet development and/or survival.

Mining incretin hormone pathways for novel therapies

The incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), are produced predominantly by enteroendocrine cells and have multiple blood glucose-lowering effects. Recent years have seen a surge of interest in understanding the basic physiology and pathophysiology of incretins and in applying this knowledge to the treatment of diabetes and obesity. Considerable gains have been made in elucidating the mechanisms controlling incretin secretion, and there is growing evidence to suggest that incretins might be involved in the rapid reversal of diabetes observed in gastric bypass patients. Here, we review these recent advances and outline the multiple strategies being pursued to exploit the potential therapeutic benefits of GIP and GLP-1.

Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain

We have previously demonstrated that glucose-dependent insulinotropic polypeptide (GIP; gastric inhibitory polypeptide) is present in the adult rat hippocampus. This finding leads to the conclusion that all members of the secretin-glucagon family of gastrointestinal regulatory polypeptides can be found in the brain. To investigate the localization of GIP-producing cells, we used immunohistochemistry on sections of the adult rat brain. High levels of GIP immunoreactivity were observed in the olfactory bulb, hippocampus, and Purkinje cells in the cerebellum. Moreover, a moderate but distinct GIP immunoreactivity was observed in the cerebral cortex, amygdala, substantia nigra, and lateral septal nucleus as well as in several nuclei in the thalamus, hypothalamus, and brainstem. GIP immunoreactivity was frequently found to colocalize with the neuronal marker NeuN but never with the glial marker glial fibrillary acidic protein. Thus, GIP appears to be mainly neuronal to its distribution. This widespread distribution of GIP-immunoreactive cells suggests the involvement of GIP in various neuronal functions and suggests that GIP may act as a neurotransmitter or neuromodulator. This is the first characterization of the anatomical distribution of GIP-immunoreactive cells in the rat brain providing an anatomical framework for future investigations regarding the functions of GIP in the central nervous system.

Indirect RT-PCR in-situ hybridization: a novel non-radioactive method for detecting glucose-dependent insulinotropic peptide

To establish indirect in-situ PCR for the detection of intestinal peptide hormones, rat intestine and a murine intestinal tumor cell line, STC 1, were used. The results exhibited intensive staining of GIP-producing K-cells. Paraformaldehyde-fixed cryostat sections yielded the best results in signal to background ratio with RT-PCR in-situ hybridization. Moreover, it was possible to elevate the positive staining signal and to reduce background staining. Digoxigenin-labeled in-situ hybridization served as a control for specificity and sensitivity of GIP (glucose-dependent insulinotropic peptide) mRNA expression on cryostat as well as paraffin sections. In conclusion, this RT-PCR in-situ hybridization protocol proves to be a specific, sensitive and reliable non-radioactive technique for the detection of intestinal peptide hormone mRNA, especially in tissues or tumor cells where the application of ISH is limited.

Detection of glucagon in pancreatic A-cells by monoclonal antibodies

The production of a mouse monoclonal antibody from a hybrid myeloma and its use for the detection of glucagon in tissue sections is reported. The hybrid clone isolated after fusion of mouse myeloma cells with hyperimmune spleen cells from a mouse previously immunized with porcine glucagon allowed us a standardized and permanent source of monoclonal antibodies in a culture cell system. The monoclonal antibody (3 GL 31) specifically reacts with pancreatic A-cells in several species including pig, rabbit, tupaia belangeri and sheep. No immunoreactivity is observed against gut cells and neurons.

Ultrastructural localization of secretin in endocrine cells of the dog duodenum by the immunogold technique. Comparison with ultrastructurally characterized S cells of various mammals

Secretin has been localized by the immunogold technique in endocrine cells of the dog duodenum--previously described as "K cells"--characterized by secretory granules with double structure consisting of a secretin-containing osmiophilic core surrounded by an argyrophil halo. Granules resembling those of dog secretin cells were also found in some ultrastructurally characterized S cells of the cat, pig, rat and rabbit duodenum, thus confirming in these species the identification of S cells with secretin cells. Conversely, the cells previously described as "S cells" in the dog lacked secretin immunoreactivity.

An immunocytochemical study of endocrine pancreas of snakes

The pancreas from eleven species of snakes representing both advanced and primitive families has been investigated for the presence of eleven regulatory peptides reported to occur in the mammalian endocrine pancreas. Of the eleven peptides studied, insulin, pancreatic glucagon and somatostatin were present in endocrine cells within the islets of all the species investigated. The neuropeptide, vasoactive intestinal polypeptide, was located within nerve terminals innervating the islets in the Boidinae, Colubrinae, Elaphidae and Crotalidae but absent from the Natricinae investigated. No immunoreactivity was demonstrable with the antisera to substance P, met-enkephalin, C-terminal gastrin, bombesin, glicentin and gastric inhibitory polypeptide. Pancreatic polypeptide-like immunoreactivity was demonstrable only in the boid snakes and exclusively stained by a C-terminal specific antiserum.

Ultrastructural localization of gastric inhibitory polypeptide (GIP) in a well characterized endocrine cell of canine duodenal mucosa

The polypeptide hormone GIP has been localized ultrastructurally by using specific, monoclonal GIP antibodies and an immunogold technique on aldehyde-osmium fixed specimens of dog duodenal mucosa. A single type of cell showing round, homogeneous, fairly osmiophilic granules with closely applied membrane and a mean size of 188 nm +/- 34 SD has been identified as the GIP cell.

Immunocytochemical localization of glucagonlike and gastric inhibitory polypeptidelike peptides in the pancreatic islets and gastrointestinal tract

The distribution of cells displaying glucagonlike or gastric inhibitory polypeptide (GIP)-like immunoreactivity was examined in the pancreatic islets and gastrointestinal tracts of rats, dogs, and humans. A-cells in the pancreatic islets in all three species were stained by antisera having regional specificity for pancreatic-type glucagon, gut-type glucagon (glicentin), or GIP. Oxyntic A-cells of the gastric mucosa in dogs and humans also were stained comparably by these three antisera. In contrast, the K- and L-cells in the intestinal mucosa of those species were stained only by antisera capable of reacting with GIP or gut-type glucagon, respectively. Tests of antibody specificity showed that the GIP antiserum did not cross-react with either pancreatic- or gut-type glucagon. Likewise, the glucagon antisera showed no cross-reactivity with GIP. Hence, these findings suggest that pancreatic and gastric A-cells contain a peptide with GIP-like immunoreactivity distinct from glucagon or glicentin per se. Although the exact basis of th GIP-like immunostaining of A-cells is unknown, it may be due to the presence of a glucagon precursor sharing certain amino-acid sequences with GIP. This hypothesis is consistent with several recent investigations showing that the processing of proglucagon molecules differs between the A- and L-cells.

Immunohistochemical identification of factor X-like antigen in the A cells of the normal human pancreas

An indirect immunofluorescence technique using two rabbit anti-human factor X sera was used to investigate the presence of factor X in various human tissues. Of all tissues studied only the cytoplasm of some islet cells of the six human pancreases illustrated specific reactivity for factor X-like material. No reaction was seen in the exocrine pancreas. Cross-absorption studies with factor X-deficient plasma, glucagon or alpha-1-antitrypsin did not modify the pattern. On the contrary, cross-absorption with factor X Friuli or with normal plasma eliminated the positivity. No factor X-like material was seen in rat or guinea pig pancreas. The double-immunofluorescence technique demonstrated that the reactivity was localized only in the cytoplasm of the A cells.

Clinical aspects of GIP secretion

The gastric inhibitory polypeptide (GIP) is the main hormone of the incretin type acting on the entero-insular axis. It is released after fat, glucose or meal ingestion. The variations of this secretion are described in obesity and in some pancreatic and gastrointestinal diseases: it is increased in maturity onset diabetes mellitus, obesity or duodenal ulcer, variable according to the food taken and the severity of the pancreatic lesion in chronic pancreatitis and cystic fibrosis, normal in insulinoma and decreased in celiac disease. The impaired absorption of the food-stuffs and the defective feed-back regulation of GIP secretion by insulin are the major causes of these variations. To a lesser degree, gastric acid secretion, gastric emptying and vagal control may also influence GIP secretion.

A comparison of the ability of serum and monoclonal antibodies to gastric inhibitory polypeptide to detect immunoreactive cells in the gastroenteropancreatic system of mammals and reptiles

A monoclonal antibody raised to gastric inhibitory polypeptide (GIP) has been compared with conventional rabbit and guinea-pig antisera to GIP. Four staining methods were tested and of these the peroxidase antiperoxidase (PAP) method proved to give the best results with both the mouse and rabbit antibodies. The monoclonal antibody, when used to stain pancreatic tissue, gave negative results whereas a distinct population of gut endocrine cells was readily demonstrable, suggesting that GIP is not a constituent of the mammalian pancreas. The monoclonal antibody was found to be the most sensitive for immunocytochemistry achieving the titre of 1:10(6) in rat gut. A C-terminal specific antibody, with a high affinity and avidity to GIP, it was clearly the preferred antibody for immunocytochemical studies.

GIP-like immunoreactivity in glucagon cells. Interactions between GIP and glucagon on insulin release

In the present study the cellular and subcellular distribution of immunoreactive glucagon and GIP (gastric inhibitory polypeptide) were studied in the mouse. Furthermore, the effects of pure GIP and glucagon on basal and stimulated insulin secretion were investigated. Immunohistochemistry revealed that immunoreactive GIP occurred in the pancreatic glucagon cells and in endocrine cells, also displaying glucagon immunoreactivity, scattered along the small and large intestines. Electron immunocytochemistry revealed that the GIP-like material and glucagon coexisted in the secretory granules of the pancreatic glucagon cells. Pure porcine GIP and glucagon both stimulated basal insulin release. When equipotent doses of the peptides were given together, the two peptides antagonized each other's effect. Both peptides potentiated glucose- and carbachol-induced insulin release. When equipotent doses of the two peptides were given together prior to the administration of each of these secretagogues their effects on insulin release were additive.

Immunohistochemical localization of gastrin C-terminus, gastric inhibitory peptide (GIP) and endorphin in the pancreas of lizards with special reference to the hibernation period

Gastrin C-terminus and GIP immunoreactive cells were observed in the pancreas of the desert lizard (Uromastyx aegyptia) captured during the hibernation period, but not in those collected in the active period. These cell types were encountered among the exocrine parenchyma, especially around ducts and among the ductal epithelial cells. Occasionally a few GIP cells were seen to occupy the islet periphery. No gastrin C-terminus or GIP immunoreactive cells were observed in the pancreas of the grass lizard (Mabuya quinquetaeniata)--which does not hibernate--collected in winter and in summer. In both species of lizards endorphin-like immunoreactivity was localized in the pancreatic PP-cells in specimens collected in winter and summer. It was assumed that the presence of the gastrin C-terminus and GIP cells in the desert lizard pancreas represents a response to the peculiar physiological state through which these lizards pass in hibernation.

Immunocytochemical demonstration of enkephalin and beta-endorphin in endocrine tumors of the rectum. A survey of 27 colo-rectal carcinoids

In a histopathological and immunocytochemical study of biopsy and/or operation specimens from 27 patients with endocrine tumors of the colon and rectum ("hind-gut carcinoids") enkephalin-immunoreactive tumor cells were observed in two cases. Both patients were obese women, about 50 years of age, with a history of constipation. The tumors were situated near the anus in the dorsal wall of the rectum. One tumor had metastasized to a lymph node, and the other showed vascular invasion. The tumor cells were non-argentaffin; some were argyrophil. One tumor contained only few enkephalin-immunoreactive cells but had numerous beta-endorphin-immunoreactive cells, which were distinct from the former. The other contained large numbers of enkephalin-immunoreactive cells but no beta-endorphin cells. Both tumors also harboured glucagon-immunoreactive cells; in one there were also cells containing immunoreactive pancreatic polypeptide. These cells were distinct from the enkephalin-storing ones. No 5-hydroxytryptamine could be detected in the two tumors.

Immunoreactivities of gastrin (G-) cells. II. Non-specific binding of immunoglobulins to G-cells by ionic interactions

Various gastro-entero-pancreatic (GEP) endocrine cells have been shown to contain concomitantly immunoreactivities against several peptide hormones. In the present study the "immunoreactivities" of gastrin (G-) cells of the rat stomach against 21 specific antisera and 10 control sera were investigated by means of the unlabelled antibody enzyme (PAP) technique using modifications of single steps in the immunocytochemical staining sequence. The results indicate that immunoglobulins can bind to gastrin cell granules obviously by non-specific ionic interactions. This non-specific binding of immunoglobulins occurs even in dilution ranges of the sera commonly used in immunohistochemical investigations of the GEP endocrine system. Since "adsorption controls" (preadsorption of the antisera with their respective antigens) will not discriminate between specific and non-specific binding of immunoglobulins to GEP endocrine cells additional specificity controls are necessary. In contrast to the immunostaining of various GEP endocrine cells by "established" antisera and of G-cells by gastrin antiserum immunoglobulins of sera from non-immunized animals as well as antibodies against corticotropin-lipotropin related peptides could be displaced from their binding sites in G-cells by alterations of the NaCl content of the buffers used as diluents or as rinsing solutions. To exclude immunostaining of GEP endocrine cells by nonspecific binding of immunoglobulins the following working procedures are recommended for immunocytochemical investigations of these cells: 1. Use of high titer antisera at low concentrations (diluted 1:1,500 or more). 2. Elevation of the salt (NaCl) content up to 0.5 M of the buffer used as diluent or as rinsing solution. 3. Adsorption controls will show reliable results only if point 1. and 2. have been taken into account.

Identification and processing of proglucagon in pancreatic islets

Immunoprecipitation and tryptic peptide analysis of newly synthesized proteins from rat islets have identified an 18,000 molecular weight (MW) protein as proglucagon. Conversion of this precursor was kinetically similar to the conversion of proinsulin and resulted in the formation of both pancreatic glucagon and a 10,000-MW protein lacking this hormonal sequence.